GC
LCTX icon

Guggenheim Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Guggenheim Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-37,290
Closed -$88K – 2503
2018
Q1 		$88K Buy
37,290
+3,323
+10% +$7.79K ﹤0.01% 2669
2017
Q4 		$63K Sell
33,967
-5,525
-14% -$12.1K ﹤0.01% 2626
2017
Q3 		$98K Buy
39,492
+1,788
+5% +$4.43K ﹤0.01% 2654
2017
Q2 		$103K Buy
37,704
+62
+0.2% +$173 ﹤0.01% 2694
2017
Q1 		$113K Buy
37,642
+83
+0.2% +$236 ﹤0.01% 2682
2016
Q4 		$119K Buy
37,559
+77
+0.2% +$236 ﹤0.01% 2754
2016
Q3 		$128K Buy
37,482
+9,339
+33% +$25.8K ﹤0.01% 2708
2016
Q2 		$64K Buy
28,143
+927
+3% +$2.27K ﹤0.01% 2767
2016
Q1 		$69K Buy
27,216
+4,771
+21% +$10.6K ﹤0.01% 2786
2015
Q4 		$74K Buy
22,445
+685
+3% +$2.05K ﹤0.01% 2864
2015
Q3 		$52K Sell
21,760
-636
-3% -$1.65K ﹤0.01% 2852
2015
Q2 		$65K Sell
22,396
-283
-1% -$1.1K ﹤0.01% 2940
2015
Q1 		$91K Buy
22,679
+3,275
+17% +$11.3K ﹤0.01% 2868
2014
Q4 		$58K Buy
19,404
+2,070
+12% +$5.6K ﹤0.01% 2904
2014
Q3 		$44K Sell
17,334
-13,954
-45% -$33.6K ﹤0.01% 2935
2014
Q2 		$77K Sell
31,288
-880
-3% -$1.99K ﹤0.01% 3034
2014
Q1 		$86K Buy
+32,168
New +$94.7K ﹤0.01% 3051
2013
Q3 		– Sell
-23,694
Closed -$76K – 3134
2013
Q2 		$76K Buy
+23,694
New +$75.9K ﹤0.01% 2856

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Guggenheim Capital's LCTX Position: Q2 2018 in Review

Guggenheim Capital sold out of Lineage Cell Therapeutics (LCTX) in Q2 2018, closing a stake of 37,290 shares — an estimated $88K sold.

Guggenheim Capital first reported a position in LCTX in Q2 2013 and held it in 18 quarters. The position peaked at $128K in Q3 2016. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2018.

  • Guggenheim Capital reported no remaining Lineage Cell Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 37,290 Lineage Cell Therapeutics shares in Q2 2018, an estimated $88K.
  • Guggenheim Capital first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 18 quarters.
  • Guggenheim Capital's Lineage Cell Therapeutics position peaked at $128K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.